Vnitr Lek 2016, 62(4):317-321

What are the effects of fixed-dose combination of candesartan and amlodipine

Jiří Vítovec1,*, Jindřich Špinar2
1 I. interní kardioangiologická klinika LF MU a FN u sv. Anny v Brně
2 Interní kardiologická klinika LF MU a FN Brno, pracoviště Bohunice

We are presenting a current view on a fixed-dose combination of amlodipine and candesartan in the treatment of hypertension. Major studies on the individual preparations as well as studies examining their combination are included. This fixed-dose combination expands our possibilities with regard to attaining the blood pressure target values, in particular in patients with risk factors or patients with comorbidities. Finally, the benefit mainly consists in the greater compliance of the patient with a minimum adverse effects.

Keywords: amlodipine; candesartan; fixed-dose combination; hypertension

Received: February 27, 2016; Accepted: April 9, 2016; Published: April 1, 2016  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vítovec J, Špinar J. What are the effects of fixed-dose combination of candesartan and amlodipine. Vnitr Lek. 2016;62(4):317-321.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rosolová H. Kombinovaná léčba arteriální hypertenze. Vnitř Lék 2013; 59(5): 366-369. Go to PubMed...
    2. Špinar J, Vítovec J, Špinarová L et al. Fixní kombinace v léčbě hypertenze. Vnitř Lék 2012; 58(7-8): 215-222.
    3. Filipovský J, Widimský J, Ceral J et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012 Doporučení České společnosti pro hypertenzi. Vnitř Lék 2012; 58(10): 785-801. Go to PubMed...
    4. Nishio K, Kondo T, Kobayashi Y. Efficacy and Tolerability of Candesartan Cilexetil and Amlodipine in Patients with Poorly Controlled Essential Hypertension. Int J Clin Med 2011; 2(2): 64-68. Go to original source...
    5. Opie LH. Calcium channel blockers. In: Opie LH, Gersh BJ. Drugs for the Heart. 8th ed. Elsevier Saunders 2013: 64-92. ISBN 978-1455733224. Go to original source...
    6. Julius S, Kjeldsen SE, Weber M et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004; 363(9426): 2022-2031. Go to original source... Go to PubMed...
    7. Slíva J. Candesartan v léčbě kardiovaskulárních onemocnění. Farmakoterapie 2012; 8(1): 118-122.
    8. Messerli FH, Bangalore S, Ruschitzka F. Angiotensin receptor blockers: baseline therapy in hypertension? Eur Heart J 2009; 30(20): 2427-2430. Go to original source... Go to PubMed...
    9. Papademetriou V, Farsang C, Elmfeldt D et al. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: the Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol 2004; 44(6): 1175-1180. Go to original source... Go to PubMed...
    10. Julius S, Kaciroti N, Egan BM et al. [TROPHY Investigators]. Outcomes based on the Seventh Report of the Joint National Committee on Hypertension definition of hypertension. J Am Soc Hypertens 2008; 2(1): 39-43. Go to original source... Go to PubMed...
    11. Ogihara T, Nakao K, Fukui T et al. Hypertensive Patients With High Cardiovascular Risks Candesartan Antihypertensive Survival Evaluation in Japan Trial. Hypertension 2008; 51(2): 393-398. Go to original source... Go to PubMed...
    12. Takai S, Jin D, Shimosato T et al. Candesartan and amlodipine combination therapy provides powerful vascular protection in stroke-prone spontaneously hypertensive rats. Hypertens Res 2011; 34(2): 245-252. Go to original source... Go to PubMed...
    13. Rakugi H, Ogihara T, Miyata Y et al. Evaluation of the efficacy and tolerability of combination therapy with candesartan cilexetil and amlodipine besilate compared with candesartan cilexetil monotherapy and amlodipine besilate monotherapy in Japanese patients with mild-to-moderate essential hypertension: a multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2012; 34(4): 838-848. Go to original source... Go to PubMed...
    14. Yasuno S, Fujimoto A, Nakagawa Y et al. Fixed-dose combination therapy of candesartan cilexetil and amlodipine besilate for the treatment of hypertension in Japan. Expert Rev Cardiovasc Ther 2012; 10(5): 577-583. Go to original source... Go to PubMed...
    15. Yamaguchi J, Hagiwara N, Ogawa H et al. Effect of amlodipine + candesartan on cardiovascular events in hypertensive patients with coronary artery disease (from The Heart Institute of Japan Candesartan Randomized Trial for Evaluation in Coronary Artery Disease [HIJ-CREATE] Study). Am J Cardiol 2010; 106(6): 819-824. Go to original source... Go to PubMed...
    16. de la Sierra A. Mitigation of calcium channel blocker-related oedema in hypertension by antagonists of the renin-angiotensin system. J Hum Hypertens 2009; 23(8): 503-511. Go to original source... Go to PubMed...
    17. Slíva J. Nová fixní kombinace v klinické praxi v ČR: candesartan + amlodipin. Farmakoterapie 2015; 11(1): 27-29.
    18. Vítovec J, Špinar J et al. Farmakoterapie kardiovaskulárních onemocnění. 2. vyd. Grada: Praha 2004. ISBN 80-247-0866-3.

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.